Summary
Read original article →
Johnson & Johnson announced a supply chain restructuring on 31 July 2026 that is largely tied to its innovative medicine segment and will see the company exit certain manufacturing and distribution facilities, with associated costs of up to $750 million. The programme is intended to consolidate the network footprint and shift capacity toward higher-value therapeutic platforms. Pharmaceutical manufacturers have been rebalancing production geography through 2026 as tariff exposure, cold-chain cost inflation and drug-pricing pressure converge.